Why I’d buy Neil Woodford’s favourite dividend stock AstraZeneca plc in 2018

2018 could be the year that AstraZeneca plc’s (LON: AZN) turnaround finally starts to take hold.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It has been a mixed year for Neil Woodford’s favourite stock AstraZeneca (LSE: AZN). Heading into the year, investors and analysts alike were skeptical about the pharmaceutical and biopharmaceutical company’s prospects. But cautious buying sent the shares up to a high of 5,500p at the end of June — ahead of the release of data from the company’s lung cancer study of its immunotherapy Imfinzi.

Unfortunately when the data was published, it didn’t live up to expectations and the shares slumped back down to 4,300p.

However, a robust set of third quarter figures, posted at the beginning of November, have helped investors regain confidence in Astra’s outlook. 

For the third quarter, the group posted core earnings per share of $1.12, ahead of the average City estimate of $1.09, while revenues were $6.2bn versus expectations of $6bn. What’s more, Astra’s CEO Pascal Soriot declared alongside these figures that earnings for the full-year would be “towards the favourable end” of the previously guided “low to mid teens percentage decline,” which pleased investors and analysts. 

Turnaround gaining traction

As stated, Astra is Neil Woodford’s favourite dividend stock and the star fund manager has allocated around 8% of both his Woodford Equity Income and Income Focus funds to the pharmaceutical giant, making it the largest holding for both funds. Woodford is betting that Astra’s treatment pipeline will yield results in the years ahead and the stock’s 4%-plus dividend yield is here to stay. 

And I believe that Woodford will be rewarded in 2018, a year that’s set to be a transformational one for Astra. Indeed, even though City analysts are expecting the firm to report a mid-single-digit decline in earnings per share for the year, the firm’s outlook should start to improve towards the end of 2018 as a string of new treatments take up the slack from declining Crestor sales.

To the beginning of November, the firm had received approvals for four new drugs and sales of existing products were growing faster than expected within emerging markets. There are still plenty of other new cancer-fighting drugs in the company’s pipeline and as these are approved for sale, the group will slowly move towards its goal of doubling revenues by 2023. 

Time to buy? 

By the end of 2018, investors should have much more clarity on Astra’s outlook and management should be able to establish if the company will return to growth in 2019. I believe it’s highly likely that growth will return in 2019 based on the recent product approvals and a slower than expected decline in Crestor sales. 

The one downside is that shares in Astra are relatively expensive. The stock currently trades at a forward P/E of around 17. In comparison, peer GlaxoSmithKline trades at a forward earnings multiple of just under 12. This valuation does not leave much room for error if the company fails to live up to expectations.

That said, I would argue that Astra deserves a high multiple due to its treatment pipeline, which has been labelled as one of the best in the sector by City analysts.  

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares in GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s what dividend forecasts could do for the BP share price in the next three years

I can understand why the BP share price is low, as oil's increasingly seen as evil. But BP's a cash…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

This FTSE 100 Dividend Aristocrat is on sale now

Stephen Wright thinks Croda International’s impressive dividend record means it could be the best FTSE 100 stock to add to…

Read more »

Investing Articles

3 shares I’d buy for passive income if I was retiring early

Roland Head profiles three FTSE 350 dividend shares he’d like to buy for their passive income to support an early…

Read more »

Investing Articles

Here’s how many Aviva shares I’d need for £1,000 a year in passive income

Our writer has been buying shares of this FTSE 100 insurer, but how many would he need to aim for…

Read more »

Female Doctor In White Coat Having Meeting With Woman Patient In Office
Investing Articles

1 incredible growth stock I can’t find on the FTSE 100

The FTSE 100 offers us a lot of interesting investment opportunities, but there's not much in the way of traditional…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Investing Articles

With an £8K lump sum, I could create an annual second income worth £5,347

This Fool explains how a second income is achievable by using a lump sum, investing in stocks, and the magic…

Read more »

Investing Articles

Here’s what dividend forecasts could do for the BT share price in the next 3 years

With the BT share price down so low, the dividend looks very nice indeed. The company's debt is off-putting, though.…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

28% revenue growth per year and down over 20% in price! Should I invest in this niche FTSE 250 company?

Oliver says this FTSE 250 company has done an excellent job bringing auctioning into the modern world. Will he invest…

Read more »